Xagrid (anagrelide hydrochloride): Risk of thrombosis including cerebral infarction upon abrupt treatment discontinuation
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
| Medicine name |
Xagrid
|
| Active substance |
Anagrelide
|
| Therapeutic area (MeSH) |
Thrombocythemia, Essential
|
| Procedure number |
EMEA/H/C/000480/II/091
|
| Regulatory outcome |
Variation
|
| DHPC type |
Safety signal
|
| Human ATC code |
L01XX35
|
| Dissemination date |
22/02/2022
|